Esperion Therapeutics, Inc.

NasdaqGM:ESPR Stock Report

Market Cap: US$474.9m

Esperion Therapeutics Valuation

Is ESPR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ESPR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ESPR ($2.47) is trading below our estimate of fair value ($165.21)

Significantly Below Fair Value: ESPR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ESPR?

Key metric: As ESPR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ESPR. This is calculated by dividing ESPR's market cap by their current revenue.
What is ESPR's PS Ratio?
PS Ratio1.6x
SalesUS$295.45m
Market CapUS$474.85m

Price to Sales Ratio vs Peers

How does ESPR's PS Ratio compare to its peers?

The above table shows the PS ratio for ESPR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.5x
RVNC Revance Therapeutics
1.6x21.9%US$398.6m
SNDL SNDL
0.8x7.2%US$520.4m
XERS Xeris Biopharma Holdings
2.4x17.2%US$456.2m
ELTP Elite Pharmaceuticals
9.3xn/aUS$708.8m
ESPR Esperion Therapeutics
1.6x31.1%US$474.9m

Price-To-Sales vs Peers: ESPR is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (3.5x).

Price to Sales Ratio vs Industry

How does ESPR's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

71 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x-0.06%US$3.79b
PRGO Perrigo
0.8x3.4%US$3.70b
BHC Bausch Health Companies
0.3x1.5%US$3.01b
SNDL SNDL
0.8x7.2%US$520.38m
ESPR 1.6xIndustry Avg. 2.5xNo. of Companies71PS03.67.210.814.418+
71 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ESPR is good value based on its Price-To-Sales Ratio (1.6x) compared to the US Pharmaceuticals industry average (2.5x).

Price to Sales Ratio vs Fair Ratio

What is ESPR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ESPR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.6x
Fair PS Ratio7.3x

Price-To-Sales vs Fair Ratio: ESPR is good value based on its Price-To-Sales Ratio (1.6x) compared to the estimated Fair Price-To-Sales Ratio (7.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ESPR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.47
US$7.51
+204.0%
57.8%US$16.00US$2.05n/a6
Nov ’25US$2.03
US$7.58
+273.6%
56.0%US$16.00US$2.50n/a6
Oct ’25US$1.61
US$7.59
+371.5%
55.8%US$16.00US$2.55n/a6
Sep ’25US$1.83
US$7.59
+314.8%
55.8%US$16.00US$2.55n/a6
Aug ’25US$2.18
US$7.36
+237.8%
57.6%US$16.00US$2.55n/a7
Jul ’25US$2.34
US$7.36
+214.7%
57.6%US$16.00US$2.55n/a7
Jun ’25US$2.16
US$7.41
+243.3%
56.4%US$16.00US$2.90n/a7
May ’25US$2.04
US$7.41
+263.4%
56.4%US$16.00US$2.90n/a7
Apr ’25US$2.79
US$7.41
+165.7%
56.4%US$16.00US$2.90n/a7
Mar ’25US$2.55
US$7.41
+190.8%
56.4%US$16.00US$2.90n/a7
Feb ’25US$2.07
US$8.54
+312.7%
71.3%US$22.00US$2.80n/a7
Jan ’25US$2.99
US$8.25
+175.9%
69.8%US$22.00US$2.00n/a8
Dec ’24US$1.44
US$8.25
+472.9%
69.8%US$22.00US$2.00n/a8
Nov ’24US$0.86
US$11.13
+1,195.1%
62.5%US$22.00US$2.00US$2.038
Oct ’24US$0.98
US$11.13
+1,035.2%
62.5%US$22.00US$2.00US$1.618
Sep ’24US$1.56
US$10.28
+558.8%
67.9%US$22.00US$2.00US$1.839
Aug ’24US$1.69
US$10.28
+508.2%
67.9%US$22.00US$2.00US$2.189
Jul ’24US$1.39
US$10.50
+655.4%
67.3%US$22.00US$1.00US$2.349
Jun ’24US$1.33
US$10.08
+657.5%
69.7%US$22.00US$1.00US$2.1610
May ’24US$1.42
US$11.20
+688.7%
63.0%US$22.00US$1.00US$2.0410
Apr ’24US$1.59
US$10.45
+557.5%
68.2%US$22.00US$1.00US$2.7911
Mar ’24US$6.00
US$11.38
+89.6%
50.7%US$22.00US$3.00US$2.5512
Feb ’24US$6.40
US$11.00
+71.9%
55.5%US$22.00US$3.00US$2.0711
Jan ’24US$6.23
US$11.00
+76.6%
55.5%US$22.00US$3.00US$2.9911
Dec ’23US$6.94
US$11.27
+62.4%
52.7%US$22.00US$3.00US$1.4411
Nov ’23US$8.28
US$10.82
+30.7%
57.2%US$22.00US$3.00US$0.8611

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Collegium Pharmaceutical

US$967.5m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.41

7D

0.5%

1Y

17.1%

IQVIA Holdings

US$35.3b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$197.60

7D

-2.6%

1Y

-5.7%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.86

7D

-5.2%

1Y

8.0%